Oct 23rd, 2024
Featured Science for Saturday
Check out these featured studies.
FS.01: Featured Science | Novel Approaches to Managing Lipid Risk
1:30-2:45 p.m. | S100A
- Long-Term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72-Week Open-Label Extension Trial (LIBerate-OLE)
- Efficacy and Safety of Lerodalcibep, a Third-Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (LIBerate-HeFH_OLE)
- PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults With Genetically or Clinically Defined Familial Chylomicronemia Syndrome (FCS) at High Risk of Acute Pancreatitis (AP)
- Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study
FS.02: Featured Science | Health Technology and the Future of Clinical Trials
1:30-2:45 p.m. | S104B
- Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials (DELIVER)
- Manual vs. AI-Assisted Clinical Trial Screening Using Large-Language Models (MAPS-LLM)
- Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care: A Randomized Parallel Group Trial (MyoMobile Study)
- Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECH-Rehab Randomized Controlled Trial (mTECH-Rehab)
